BIOEOTC

Bio Essence Corp

Healthcare·Oncology·Irvine, CA, United States
OncologyReproductive

Bio Essence Corp (BIOE): 1 pipeline candidate · ~2 mo cash runway · 2 clinical trials. Updated within the last hour.

4.6/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway0.5

1.9 months

Financial Health10.0

D/E -1.55 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Bio Essence Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$11.8M

Cash

$36K

Quarterly Burn

$412K

Runway

1.9 mo

Revenue

$501K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

2 clinical trials·CEO: Ms. Yin Yan J.D., M.B.A.

Frequently asked questions

How many drug candidates are in Bio Essence Corp's pipeline?

Bio Essence Corp (BIOE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Bio Essence Corp's lead drug candidate?

Bio Essence Corp's most advanced tracked candidate is Traditional Chinese medicine for tonifying the kidney (N/A) for Intrauterine Adhesion.

What is Bio Essence Corp's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Bio Essence Corp has approximately 1.9 months of cash runway.

What is Bio Essence Corp's market capitalization?

Bio Essence Corp's market capitalization is approximately $11.8M.

Who is the CEO of Bio Essence Corp?

Ms. Yin Yan J.D., M.B.A. is the chief executive officer of Bio Essence Corp (BIOE).

Get the full picture on Bio Essence Corp

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.